TickerGuard
Buy Day today: Neutral (61) Mixed market breadth · no major macro event
UNCY

Unicycive Therapeutics Inc

Healthcare · Biotechnology

3.80$ +3.3% vs. previous close Closing price · As of: Nov 11, 2026

Ownership

Ownership Structure

Who owns Unicycive Therapeutics Inc (UNCY)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 99.3% of the shares are freely tradable; institutional investors hold 41.9%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 41.9%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 2.4%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 99.3%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 17.9%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 27Mio.

Largest Shareholders

Institutions

Institutions UNCY
Name Stake (%) Shares Change (%) Date
Nantahala Capital Management, LLC 10.06 2,802,894 +198.4 06/30/2026
BlackRock Inc 5.07 1,413,381 +3,836.7 06/30/2026
Vanguard Capital Management, LLC 3.85 1,071,481 +32.0 06/30/2026
Octagon Capital Advisors LP 3.59 1,000,000 +0.0 06/30/2026
Geode Capital Management, LLC 2.02 564,019 +176.8 06/30/2026
Vivo Capital, LLC 1.97 550,000 -69.3 06/30/2026
Marshall Wace Asset Management Ltd 1.97 547,862 +253.6 06/30/2026
Logos Global Management LP 1.70 473,563 +0.0 06/30/2026

Funds

Funds UNCY
Name Stake (%) Shares Change (%) Date
Vanguard MStar Total Stk Mkt Idx Invest 2.89 805,716 +0.0 09/30/2026
iShares Russell 2000 ETF 2.16 602,552 -0.4 10/29/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: November 11, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?